The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
26 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,126,757 in first-year total cost, median $258,482.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (03)]8
- Special Emphasis Panel[ZDA1 GXM-A (15)]7
- Special Emphasis Panel[ZDA1 GXM-A (01)]4
- Special Emphasis Panel[ZDA1 GXM-A (24)]4
- Special Emphasis Panel[ZDA1 GXM-A (02)]3
Most frequent institutions
- Q2I, LLC2
- ALTALITY, INC.1
- ALTRUMED LLC1
- ARREVUS, INC.1
- CONSEGNA PHARMA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Designing and validating optimal nonaddictive analgesics using the CANDO paradigm1R41DA056273-01 | MANGIONE, WILLIAM T | MEDITATI INC., NY | $320,649 | ZDA1 |
| 2023 | The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone1R41DA056276-01 | BRENNER, JACOB | ALTRUMED LLC, PA | $319,930 | ZDA1 |
| 2023 | Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain1R41DA056250-01 | VRABEC, TINA LOUISE | H-CUBED, INC., OH | $260,384 | ZDA1 |
| 2023 | PARCA (a digital tool) to improve Justice and Health1R42DA056255-01 | TAXMAN, FAYE S | Q2I, LLC, NH | $256,009 | ZDA1 |
| 2022 | Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder1R41DA056254-01 | TRAYNOR, JOHN R. | ELEVEN THERAPEUTICS CORP, CA | $320,000 | ZDA1 |
| 2022 | Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression1R41DA056270-01 | SCHARR, ALEXANDRA LAUREL | OLFA THERA, INC., CA | $320,000 | ZDA1 |
| 2022 | Virtual Reality Facilitation of Recovery from Opioid Use Disorder1R41DA055405-01 | NELSON, ANDREWOBERLIN, BRANDON | RELATE XR, LLC, IN | $319,542 | ZDA1 |
| 2022 | Leptin Receptor Agonist as a Novel Prevention of Opioid Induced Respiratory Depression1R41DA056239-01 | KRAUS, CARL NEILPOLOTSKY, VSEVOLOD Y | ARREVUS, INC., NC | $318,971 | ZDA1 |
| 2022 | A Lateral Flow Assay for Rapid Saliva Fentanyl Detection (sFENTANYL)1R43DA055415-01 | UDDIN, MD MEZBAHWANG, PING | INSTANOSIS, INC., DE | $256,554 | ZDA1 |
| 2021 | Portable hand-held proprietary xenon inhaler for rapid reduction of opioid withdrawal symptoms1R41DA055403-01 | BOGIN, VLADKAUFMAN, MARC J | NOBILIS THERAPEUTICS, INC., OR | $319,992 | ZDA1 |
| 2021 | Amelioration of opioid withdrawal-induced anxiety and craving with heterodyned whole body vibration1R41DA053083-01A1 | ADAMS, DANIEL NATHANSTEFFENSEN, SCOTT C | PHOTOPHARMICS, INC., UT | $319,976 | ZDA1 |
| 2021 | Development of therapeutics to treat fentanyl overdose using a validated animal model1R41DA055409-01 | TORRALVA, PHILLIP RANDOLPH | TORRALVA MEDICAL THERAPEUTICS, LLC, OR | $319,676 | ZDA1 |
| 2021 | Avoiding Adverse Opioid Outcomes with Proactive Precision Care1R41DA053877-01 | PLUMP, STEVEN R.SADHASIVAM, SENTHILKUMAR | OPALGENIX, INC., IN | $319,447 | ZDA1 |
| 2021 | Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)1R41DA053878-01 | WASHBURN, MICHELLE (MICKI) E | INNATEVR, LLC, MI | $256,580 | ZDA1 |
| 2020 | Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements1R42DA053075-01 | LE MAU, TUANPURDON, PATRICK L. | PASCALL SYSTEMS, INCORPORATED, MA | $349,937 | ZDA1 |
| 2020 | An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer1R42DA050365-01A1 | CATA, JUAN PABLOSINTON, JAMIE WYORK, CHRISTINA | ALTALITY, INC., MI | $278,747 | ZDA1 |
| 2020 | Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain1R41DA053011-01 | SHIN, DONALD KIM | CROSSCOMM, INC., NC | $255,648 | ZDA1 |
| 2020 | A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids1R41DA053079-01 | COWART, JOHN | SEACOAST SCIENCE, INC., CA | $252,131 | ZDA1 |
| 2020 | Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.1R41DA049615-01A1 | SHARAREH, SHIVATSENG, PETER | REKOVAR INC., CA | $225,000 | ZDA1 |
| 2020 | Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program1R41DA053081-01 | SEIGUER, SEBASTIANTSUI, JUDITH | EMOCHA MOBILE HEALTH, INC., MD | $224,940 | ZDA1 |
| 2020 | Drone-Delivered Naloxone System for Opioid Overdose Treatment1R41DA051293-01 | ORNATO, JOSEPH P | UAS ASSOCIATES LLC, VA | $224,725 | ZDA1 |
| 2020 | Developing and Testing the Opioid Rapid Response System1R41DA053078-01 | HECHT, MICHAELHENDERSON, CRISJAYAWARDENE, WASANTHA PARAKRAMA | REAL PREVENTION, LLC, NJ | $213,580 | ZDA1 |
| 2020 | An Immersive Virtual Reality Peer Support Application for Individuals with Opioid Use Disorder: Development and Initial Evaluation1R41DA051294-01 | HOLLON, STEVEN DENNIS | VERY REAL HELP, LLC, TN | $206,673 | ZDA1 |
| 2019 | Technology Improving Success of Medication-Assisted Treatment in Primary Care1R42DA050398-01 | JENKINS, STEVEN PAUL | Q2I, LLC, NH | $225,000 | ZDA1 |
| 2019 | Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain1R41DA050364-01 | KHANNA, RAJESH | REGULONIX, LLC, NY | $224,696 | ZDA1 |
| 2019 | Prevention of renarcotization from synthetic opioids1R41DA050386-01 | AVERICK, SAADYAH | CONSEGNA PHARMA, INC., PA | $217,970 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.